Compare DLY & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DLY | MPLT |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.8M | 822.2M |
| IPO Year | N/A | 2025 |
| Metric | DLY | MPLT |
|---|---|---|
| Price | $14.70 | $17.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $31.00 |
| AVG Volume (30 Days) | 215.9K | ★ 338.9K |
| Earning Date | 01-01-0001 | 02-28-2026 |
| Dividend Yield | ★ 8.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.26 | $12.24 |
| 52 Week High | $15.95 | $21.55 |
| Indicator | DLY | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | N/A |
| Support Level | $14.67 | N/A |
| Resistance Level | $14.92 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 53.33 | 0.00 |
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.